Evidence map›Paper›PMID 35891355›Full record

ArticleViruses2022

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.

Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, Annalisa Bergna, Barbara Rossetti, Federica Giammarino, Camilla Biba, Anna Gidari, Alessia Lai, Cesira Nencioni and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead.ACS pharmacology & translational science · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Review
  13. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Lia FiaschiDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Filippo DragoniDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-8148-9914
Elisabetta SchiaroliDepartment of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, 06129 Perugia, Italy.
Annalisa BergnaDepartment of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, Italy.
Barbara RossettiInfectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, 58100 Grosseto, Italy.
Federica GiammarinoDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Camilla BibaDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Anna GidariDepartment of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, 06129 Perugia, Italy.ORCID 0000-0002-6556-6553
Alessia LaiDepartment of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, Italy.ORCID 0000-0002-3174-5721
Cesira NencioniInfectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, 58100 Grosseto, Italy.
Daniela FrancisciDepartment of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, 06129 Perugia, Italy.ORCID 0000-0001-8752-8278
Maurizio ZazziDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-0344-6281
Ilaria VicentiDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-4306-2960
University of Siena · ITUniversity of Perugia · ITOspedale Misericordia - Grosseto · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newly emerging SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. By using live virus assays, we assessed the ex vivo inhibition of the B.1 wild-type (WT), delta and omicron BA.1 and BA.2 lineages by post-infusion sera from 40 individuals treated with bamlanivimab/etesevimab (BAM/ETE), casirivimab/imdevimab (CAS/IMD), and sotrovimab (SOT) as well as the activity of remdesivir, nirmatrelvir and molnupiravir. mAbs and drug activity were defined as the serum dilution (ID

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsHumansMembrane GlycoproteinsNeutralization TestsSpike Glycoprotein, CoronavirusViral Envelope ProteinsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsbamlanivimabcasirivimabetesevimabimdevimabMembrane GlycoproteinssotrovimabSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Envelope Proteinscell-based assaymAbsmicroneutralization assaymolnupiravirnirmatrelviromicron sublineagesremdesivirSARS-CoV-2

Identifiers

PMID35891355
PMCPMC9321742
OpenAlexW4283391912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.